Cargando…

Active-State Model of a Dopamine D(2) Receptor - Gα(i) Complex Stabilized by Aripiprazole-Type Partial Agonists

Partial agonists exhibit a submaximal capacity to enhance the coupling of one receptor to an intracellular binding partner. Although a multitude of studies have reported different ligand-specific conformations for a given receptor, little is known about the mechanism by which different receptor conf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kling, Ralf C., Tschammer, Nuska, Lanig, Harald, Clark, Timothy, Gmeiner, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059746/ https://www.ncbi.nlm.nih.gov/pubmed/24932547 http://dx.doi.org/10.1371/journal.pone.0100069

Ejemplares similares

Active-State Models of Ternary GPCR Complexes: Determinants of Selective Receptor-G-Protein Coupling
por: Kling, Ralf C., et al.
Publicado: (2013)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
por: Sumi, Satoko, et al.
Publicado: (2022)

Comparative MD Simulations Indicate a Dual Role for Arg132(3.50) in Dopamine-Dependent D2R Activation
por: Kling, Ralf C., et al.
Publicado: (2016)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level
por: Tabor, Alina, et al.
Publicado: (2016)

S37. STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
por: Sonnenschein, Susan, et al.
Publicado: (2018)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

Identification of the Beer Component Hordenine as Food-Derived Dopamine D2 Receptor Agonist by Virtual Screening a 3D Compound Database
por: Sommer, Thomas, et al.
Publicado: (2017)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
por: Kelly, Deanna L, et al.
Publicado: (2013)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Agonist and Antagonist Effects of Aripiprazole on D(2)-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone
por: Ma, Guo Fen, et al.
Publicado: (2015)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
por: Murphy, Anna, et al.
Publicado: (2016)

The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells
por: Kundu, Namita, et al.
Publicado: (2019)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Aripiprazole, A Drug that Displays Partial Agonism and Functional  Selectivity
por: Tuplin, Erin W., et al.
Publicado: (2017)

Structure-Based Evolution of Subtype-Selective Neurotensin Receptor Ligands
por: Schaab, Carolin, et al.
Publicado: (2014)

Attenuation of chemokine receptor function and surface expression as an immunomodulatory strategy employed by human cytomegalovirus is linked to vGPCR US28
por: Frank, Theresa, et al.
Publicado: (2016)

Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole
por: Osuna-Luque, Jaime, et al.
Publicado: (2018)

Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists
por: Wang, Haoqing, et al.
Publicado: (2022)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Optimizing the Expression of Human Dopamine Receptors in Escherichia coli
por: Boritzki, Vanessa, et al.
Publicado: (2021)

In Silico Adoption of an Orphan Nuclear Receptor NR4A1
por: Lanig, Harald, et al.
Publicado: (2015)

Real time monitoring of membrane GPCR reconstitution by plasmon waveguide resonance: on the role of lipids
por: Calmet, Pierre, et al.
Publicado: (2016)

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
por: de Bartolomeis, Andrea, et al.
Publicado: (2015)

Dopamine receptor D(2) activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK
por: Lee, Hyounji, et al.
Publicado: (2019)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Aripiprazole in the acute and maintenance phase of bipolar I disorder
por: Zupancic, Melanie, et al.
Publicado: (2012)

Basal Histamine H(4) Receptor Activation: Agonist Mimicry by the Diphenylalanine Motif
por: Wifling, David, et al.
Publicado: (2019)

Stabilization of Interdomain Interactions in G protein α(i) Subunits Determines Gα(i) Subtype Signaling Specificity
por: Lefevre, Tyler J., et al.
Publicado: (2023)

Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine‐Derived Phenylazocarboxamides as Novel μ‐Opioid Receptor Ligands
por: Krüll, Jasmin, et al.
Publicado: (2020)

Structure-based development of caged dopamine D(2)/D(3) receptor antagonists
por: Gienger, Marie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kjh1a820t1ft7m2nojrhkrbj71